Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Somebody felt the need to paint the close? That's desperation.
How's that working for you? Buy the rumor sell the news. Massive dilution will never be able to maintain. Those that bought premarket are kicking themselves even harder.
Summer 2021. Berotralstat not coming out til end of 2020. Anything is possible though with galidesivir. Could be millions this summer. But that's where the speculation comes in.
True, but news does not equate to dollars. When biocryst starts selling drugs with positive revenue streams the valuation will be much higher than it us now. Most looking at this as speculative so flipping is easy. Long term investors sit back, relax, and enjoy the ride.
Simple market reactions. No shorties, no evil mm's. The fact that the story is now worry about second wave actually plays in our favor. Covid remaining at the forefront is better for all drug companies working on cure/vaccines etc. Still a bonus for us as berotralstat is still our number one money maker this year. Galidesivir may be too but just too early to tell. Solid company with solid results. Its the future potential that should have prople buying on these market dips.
Nope, pumpers all the same. No reality. Over bought. Whoever bought at 1.45 now kicking themselves. Continued losses, continued dilution. Those are facts. Hope is not an investment strategy.
Buy the rumor, sell the news!
Quite well. When it dipped below .95 this morning quite profitable. Spiked to above 1.40 and now dropping, oh quite profitable! Stock already overbought. Play the game!
You forgot net loss of 19.5 million dollars (canadian). Not to mention the continued dilution to keep operations going. A double wammy.
On May 21, 2020 HEXO closed a $57.5M underwritten public offering for the purchase and sale of 55,600,000 units and 8,340,000 over-allotment units. Each unit is comprised of one common share and one-half common share purchase warrant at an offering price of $0.90 per unit. The warrants have a five year-term and an exercise price of $1.05 per share.
That's where the Houston disaster team disappeared to. You just can't tell the truth can you?
So what's the name of the pizzeria and do ltnc shareholders have an interest in the business? Where is the money coming from?
No, fraud! Pumping another loser I see. Such a sad individual the CEO is!
You mean .80
I agree. Like I said before, this CEO knows what he's doing. He only releases verifiable facts. Not conjecture. Keeps the company out of trouble especially after the pump dump and lawsuites of srne.
It will take time, ultimately the major rise is when it is fully distributable to the masses and revenue keeps flowing in. For now its a great time to add shares before the rise to 20.00
New data
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced new data published in Science Translational Medicine show, in a primate model, that galidesivir was safe, provided post-exposure prevention of Zika viral replication across a range of doses, and rapidly reduced viral loads to undetectable levels when dosed up to 72 hours after infection with Zika virus.
“Galidesivir reduced Zika virus replication from the first dose administered without impairing the adaptive immune response that protects against subsequent infection. These data provide an encouraging foundation for studying SARS-CoV-2, another RNA-replicating virus, in this same animal species,” said James B. Whitney, Ph.D., assistant professor of medicine at Harvard Medical School and lead author of the study.
“The rapid reduction in Zika viral load we see in this robust animal model further demonstrates the broad antiviral potential of galidesivir against multiple pathogens. The current COVID-19 pandemic has reinforced the urgent global need for effective broad-spectrum antiviral therapies to combat these outbreaks,” said Dr. William Sheridan, chief medical officer of BioCryst.
Galidesivir is an investigational broad-spectrum antiviral drug that was safe and well tolerated in previously reported Phase 1 trials in healthy subjects. Galidesivir has demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including the coronaviruses that cause MERS and SARS. A Phase 1 trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19 is currently enrolling patients across multiple sites in Brazil.
Zika Study Details
In the Zika virus study of galidesivir, 70 Rhesus macaques were studied with different routes of infection, different doses of galidesivir, and galidesivir treatment initiated at different time points after infection. Endpoints included Zika virus RNA quantity in plasma, saliva, urine, and cerebrospinal fluid (CSF), and a variety of immunologic measurements, including antibody seroconversion to Zika virus. Galidesivir was safe and showed robust antiviral activity at all stages of Zika infection and at multiple different doses. Zika-infected animals that were treated with galidesivir developed an immune response to Zika that was protective against subsequent Zika re-challenge.
About Galidesivir (BCX4430)
Galidesivir, a broad-spectrum antiviral drug, is an adenosine nucleoside analog that acts to block viral RNA polymerase. It is in advanced development for the treatment of COVID-19, Marburg virus disease and Yellow Fever. Phase 1 clinical safety and pharmacokinetics trials of galidesivir by both intravenous and intramuscular routes of administration in healthy subjects have been completed. In animal studies, galidesivir has demonstrated activity against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses. Galidesivir has also demonstrated broad-spectrum activity in vitro against more than 20 RNA viruses in nine different families, including coronaviruses, filoviruses, togaviruses, bunyaviruses, arenaviruses, paramyxoviruses, and flaviviruses. BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
I agree they are the perfect candidate for any major drug company to absorb. As for shareholders we'd make more money if they stay independent with accelerated growth and become a major player themselves. Very possible with the govt funding/backing and their list of successful drugs.
Forgot to add the Tyr Equity scam. And the boss equity scam.
That would be nice also, but would limit our gains. I own PHE and GSK but wouldn't want them to buy as then the bcrx drugs become a small percentage of their entire portfolio. The gains are then absorbed by the bigger portfolio the major drug companies have. If a buyout is announced. I would sell on the premium and find the next buyout candidate.
See below for the latest tweet. Can the ceo really have faith in God when he continues to defraud his shareholders? To never admit all his many lies and shady dealings? Is it really faith in God when he refuses to inform shareholders of the financial status of the company and details behind his red phoenix pizzeria scam? Is it faith or is the CEO using this line to hide his true nature. The wolf in sheeps clothing? Looks like Schadel has more faith in his gambling losses and his bottle of booze more than in his god! Shameful he can't confess his sins and tell the truth. The secret is out regardless of what he thinks he's hiding. God sees it all. Hell awaits this man.
LTNC
AFPW
TSGL
RED PHOENIX
PUMPING IHSI AND SAKL scams.
IRS Lien
Toxic Debts
Houston disaster team lies.
Ryan Schadel
@CRyanSchadel
I'm here to tell you folks, "the Secret" is absolutely 100% real. BUT, there's an even BIGGER Secret about the Secret. The true power of it comes from faith in God. That's the real secret.
7:59 AM · Jun 10, 2020
I'm not expecting much until revenue starts to stream in. End of year. All else will be speculation. So looking to add to position as time goes along. If things advance more quickly it will be a bonus.
Another pr! always good news. BioCryst Announces Berotralstat Expanded Access Program for Patients with Hereditary Angioedema in United States
worthless info, no utah, no new york. no working processor, no employees, no waste facilities, no deals. no joke!
Exactly my point with the Chinese connection. But how did message boards get the info when they didn't announce it until 31 December. The issue is chinese may be taking advantage of their own error and purposely doing so. I do not trust Ji or anything that comes out of srne. The lawsuits will shut this down.
Double is my minimum. Any more is a bonus. But I agree here, based on fundamentals and real possibilities, 20 dollars will be achieved it just might take to Dec 2021 to achieve.
Good luck following them. I stick with the professionals. Only on Ihub as I follow a few scams and waiting for justice to be served. For stock advice I use my broker and professional analysts. Definitely not worried about short term movements. 1 to 2 years out to double my money is the goal. The rest is bs IMO.
I just looked at what Reddit is. What a joke. For a second I thought you were serious. Now I see why people thought what they did. I'll stick with the professionals and not social opinionated and manipulated websites.
chat boards and a pump site does not give any speculation legitimacy. this isn't otc or stinky pinkys. Professional analysts such as Jefferies are what matter. Maybe there is too much otc thinking here.
for the sake of argument lets say you recall correctly. But whose speculation?. I find no one speculating about galidesivir at that time. Not the analysts nor any major entity. Only speculation is on these message boards which we all know mean and influence absolutely nothing. The 52 week high coincides with srne cure pump bs.
The rise to 6 had nothing to do with bcrx specifically. It was a piggy back on srne's bs cure pr which raised the entire bio index. Now we rise on our own accord. When pps is 20. This little dip and hold will be forgotten.
Works for me. After 5 percent gain yesterday a pause is good.
From the CDC:
The outbreak of coronavirus disease (COVID-19) was first reported on December 31, 2019, in Wuhan, China (1).
So you're saying a practically broke and suffering pharma co in California got the word the day after? Pr just more unsubstantiated bs.
What's bothersome is their PR that states the below quote. Being a Chinese owned, run, and manipulative company, they were already working on a "cure" since the beginning of the year? Just when did they know about covid 19 and how did they know?
Since the beginning of the year, Sorrento has embarked on a multipronged strategy to search for and develop potent antidotes to the SARS-CoV-2 virus of COVID-19
I think its great. Put my winnings into bcrx. I'm playing the drug game. Still need to hit 40.00 for me to break even with my 3800 shares. Good to see though.
So what liens and debts have you left the shareholders? Oh and are LTNC shareholders co owners of your pizza establishmwnt or are you just using their money?
Hindsite is always 20/20. Like watching texas holdem and seeing everyones hands. Reality is much different. Diversification is key. BCRX CEO knows what he's doing. When he has results, he'll publish. Also do not think the major analysts have forgotten. They are watching intently on progress of gal. And ber. Still a long way to 31 Dec. This stock should not be for flippers or weak hands. Staying the course as their drugs have life changing result possibilities.
Hard to believe this scam is still trading and you're still pushing it.
I'll take a 5 percent gain any day. Good support also.
If they don't have supply issues. But whats great is there is plenty of room for multiple drugs. Galidesivir is taken orally whereby remdesivir is IV. Both useful but oral, if proven effective, can and will be used out of hospital environment, Good luck to all.
fortunately there's plenty of room for multiple drugs. bcrx drug is oral whereby gild's is via IV. If successful the oral method will take the majority of market share.
And gilead is running out of remdesivir. Our CEO should, and probably is, pushing the govt to take a very close look at galidesivir. Would definitely be a plus if moved to the front of the line.